ENDURANCE Trial: Can Myeloma Patients Stop Revlimid Maintenance After 2 Years? | IMS 2026

Sagar Lonial, MD, of Winship Cancer Institute of Emory University discusses the ENDURANCE trial comparing VRd and KRd and the duration of Revlimid (lenalidomide) maintenance at IMS 2026 in Glasgow. The trial found no difference between VRd and KRd for standard-risk patients, and two years of maintenance did as well as indefinite maintenance. He explains how these results fit today's four-drug treatments, why he favors MRD-guided discussions about stopping, and why patients should talk with their doctor.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:
0:00 Introduction and ENDURANCE trial design
0:44 Second question: two years vs. indefinite Revlimid
1:11 What the results mean for maintenance
1:32 Stopping maintenance based on MRD
2:22 Biggest takeaway for patients on Revlimid